Literature DB >> 8054436

Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial.

J McAuley1, K M Boyer, D Patel, M Mets, C Swisher, N Roizen, C Wolters, L Stein, M Stein, W Schey.   

Abstract

Between December 1981 and May 1991, 44 infants and children with congenital toxoplasmosis were referred to our study group. A uniform approach to evaluation and therapy was developed and is described herein along with the clinical characteristics of these infants and children. In addition, case histories that illustrate especially important clinical features or previously undescribed findings are presented. Factors that contributed to the more severe disabilities included delayed diagnosis and initiation of therapy; prolonged, concomitant neonatal hypoxia and hypoglycemia; profound visual impairment; and prolonged, uncorrected increased intracranial pressure with hydrocephalus and compression of the brain. Years after therapy was discontinued, three children developed new retinal lesions (without loss of visual acuity when therapy for Toxoplasma gondii was initiated promptly), and three children experienced a new onset of afebrile seizures. Most remarkable were the normal developmental, neurological, and ophthalmologic findings at the early follow-up evaluations of many--but not all--of the treated children despite severe manifestations, such as substantial systemic disease, hydrocephalus, microcephalus, multiple intracranial calcifications, and extensive macular destruction detected at birth. These favorable outcomes contrast markedly with outcomes reported previously for children with congenital toxoplasmosis who were untreated or treated for only 1 month.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8054436     DOI: 10.1093/clinids/18.1.38

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  74 in total

1.  Toxopain-1 is critical for infection in a novel chicken embryo model of congenital toxoplasmosis.

Authors:  Xuchu Que; Annette Wunderlich; Keith A Joiner; Sharon L Reed
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

Review 2.  Long-Term Relationships: the Complicated Interplay between the Host and the Developmental Stages of Toxoplasma gondii during Acute and Chronic Infections.

Authors:  Kelly J Pittman; Laura J Knoll
Journal:  Microbiol Mol Biol Rev       Date:  2015-12       Impact factor: 11.056

3.  Reply to Wallon and Peyron.

Authors:  Rima McLeod; Kelsey M Wheeler; Kenneth Boyer
Journal:  Clin Infect Dis       Date:  2015-12-21       Impact factor: 9.079

Review 4.  Toxoplasmosis: A history of clinical observations.

Authors:  Louis M Weiss; Jitender P Dubey
Journal:  Int J Parasitol       Date:  2009-02-13       Impact factor: 3.981

Review 5.  Survey of European programmes for the epidemiological surveillance of congenital toxoplasmosis.

Authors:  A Bénard; E Petersen; R Salamon; G Chêne; R Gilbert; L R Salmi
Journal:  Euro Surveill       Date:  2008-04-10

6.  Development of specific immunoglobulins G, M, and A following primary Toxoplasma gondii infection in pregnant women.

Authors:  P A Jenum; B Stray-Pedersen
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

7.  Common questions about the diagnosis and management of congenital toxoplasmosis.

Authors: 
Journal:  Paediatr Child Health       Date:  1999-03       Impact factor: 2.253

8.  Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii.

Authors:  Kamal El Bissati; Aziz A Chentoufi; Paulette A Krishack; Ying Zhou; Stuart Woods; Jitender P Dubey; Lo Vang; Joseph Lykins; Kate E Broderick; Ernest Mui; Yasuhiro Suzuki; Qila Sa; Stephanie Bi; Nestor Cardona; Shiv K Verma; Laura Fraczek; Catherine A Reardon; John Sidney; Jeff Alexander; Alessandro Sette; Tom Vedvick; Chris Fox; Jeffrey A Guderian; Steven Reed; Craig W Roberts; Rima McLeod
Journal:  JCI Insight       Date:  2016-09-22

9.  Evaluation of DPC immulite 2000 Toxoplasma quantitative IgG/IgM kits for automated toxoplasmosis serology with immulite 2000.

Authors:  Florence Robert-Gangneux; Chantal Bourhis; Sylviane Chevrier; Jean-Pierre Gangneux
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

10.  Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.

Authors:  Gang Cheng; Stephen P Muench; Ying Zhou; Gustavo A Afanador; Ernest J Mui; Alina Fomovska; Bo Shiun Lai; Sean T Prigge; Stuart Woods; Craig W Roberts; Mark R Hickman; Patty J Lee; Susan E Leed; Jennifer M Auschwitz; David W Rice; Rima McLeod
Journal:  Bioorg Med Chem Lett       Date:  2013-02-13       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.